Nasdaq Cort News Today

StockNews.com lowered shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) from a strong-buy rating to a buy rating in a report published on Friday morning. Several other brokerages have also weighed in on CORT. Truist Financial increased their price objective on shares of Corcept Therapeutics from $42.00 to $44.00 and gave the stock a buy […]

StockNews.com lowered shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) from a strong-buy rating to a buy rating in a research note published on Friday. Other equities research analysts have also issued research reports about the company. Truist Financial increased their price target on Corcept Therapeutics from $42.00 to $44.00 and gave the stock a […]

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Joseph Douglas Lyon sold 10,830 shares of the company’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $26.00, for a total transaction of $281,580.00. Following the transaction, the insider now owns 7,314 shares of the company’s stock, […]

Corcept Therapeutics (NASDAQ:CORT – Free Report) had its price objective upped by HC Wainwright from $38.00 to $40.00 in a research note published on Thursday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Corcept Therapeutics’ Q2 2024 earnings at $0.21 EPS, Q3 2024 earnings […]

Corcept Therapeutics (NASDAQ:CORT – Free Report) had its price objective boosted by HC Wainwright from $38.00 to $40.00 in a research note issued to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Corcept Therapeutics’ Q2 2024 earnings at $0.21 […]

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) is scheduled to announce its earnings results after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of $0.18 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link. Corcept Therapeutics (NASDAQ:CORT – […]

HC Wainwright reissued their buy rating on shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) in a report issued on Tuesday morning, Benzinga reports. HC Wainwright currently has a $38.00 price target on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the stock. Truist Financial lifted their price target on […]

Hussman Strategic Advisors Inc. cut its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 16.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,500 shares of the biotechnology company’s stock after selling 10,500 shares during the period. Hussman Strategic Advisors […]

MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Joseph Douglas Lyon sold 5,443 shares of the firm’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $26.00, for a total transaction of $141,518.00. Following the completion of the transaction, the insider now directly owns 7,314 shares […]